The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Analysts

Analysts following Diamyd Medical:
Maria Karlsson Osipova, DNB Carnegie . Maria.Karlsson.Osipova@dnbcarnegie.se

  Year-end Report, Ocober 8, 2025

The fiscal year 2024/2025 has been a transformative and defining period for Diamyd Medical. With only six months remaining until the planned first readout of our registrational Phase 3 trial DIAGNODE-3, we have advanced with precision, focus, and conviction across every strategic front: clinical, regulatory, manufacturing, and financial.

Recruitment in DIAGNODE-3 now exceeds 275 randomized individuals with Stage 3...

We see a clear potential to establish Diamyd® as the first precision immunotherapy that safely and effectively modifies the course of Stage 3 Type 1 Diabetes.
Ulf Hannelius, President and CEO

Calendar

  
Data pager
Data pager
123
October 25 − October 27, 2025
Breakthrough T1D Mission Summit
November 5 − November 8, 2025
ISPAD 2025
November 13, 2025
Annual Report
Annual Report 2025
November 24 − November 26, 2025
Deutsches Eigenkapitalforum
 

Diamyd Medical

Developing precision medicine therapies for the prevention and treatment of autoimmune diabetes

 

Ten largest shareholders as of June 30, 2025

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 16 830 376 12.24 9.96
Lindkvist, Bertil 8 925 000 6.49 5.28
Nordnet Pension 7 682 064 5.59 4.54
Essen-Möller, Anders * 1 135 620 3 219 040 3.17 8.62
Nordica Life 2 312 500 1.68 1.37
Essen-Möller, Maria-Teresa 400 000 963 998 0.99 2.94
Pictet and CIE (Eureope), Succurs, Ale de Lux 1 250 000 0.91 0.74
SEB Life International Insurance 1 046 901 0.76 0.62
Möller, Vidar 1 029 420 0.75 0.61
Konstruktions o Försäljningsaktiebolag 906 250 0.66 0.54
Remaining shareholders 1 967 500 89 831 054 66.76 64.79
Total 3 503 120 133 996 603 100.0 100.0

Order GAD for preclinical research

GAD PRODUCTS